Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons With Post-COVID-19 Condition

NCT05047952 is registered in ClinicalTrials.gov with Brain and Cognition Discovery Foundation as lead sponsor.

NCT NCT05047952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05047952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons With Post-COVID-19 Condition
Lead sponsor
Brain and Cognition Discovery Foundation
Phase
Phase 2
Overall status
Completed
Start date
September 16, 2021
Completion date
February 22, 2023
Enrollment
149 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, post-covid-19 condition, post-covid-19 syndrome